Baseline Imaging Derived Predictive Factors of Response Following [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
Earlier studies have mostly identified pre-therapeutic clinical and laboratory parameters for the prediction of treatment response to [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic castration resistant prostate cancer patients (mCRPC). The current study investigated whether imaging-derived...
Main Authors: | Esmée C. A. van der Sar, Adinda J. S. Kühr, Sander C. Ebbers, Andrew M. Henderson, Bart de Keizer, Marnix G. E. H. Lam, Arthur J. A. T. Braat |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/7/1575 |
Similar Items
-
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01) -
Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Sebastian Gaal, et al.
Published: (2023-10-01) -
Single Center Experience with a 4-Week <sup>177</sup>Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Jukka Kemppainen, et al.
Published: (2022-12-01) -
Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01) -
Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)